Research

Residential Air Pollution and Associations with Wheeze and Shortness of Breath in Adults: A Combined Analysis of Cross-Sectional Data from Two Large European Cohorts

Dany Doiron,^{1,2,3} Kees de Hoogh,^{2,3} Nicole Probst-Hensch,^{2,3} Stéphane Mbatchou,¹ Marloes Eeftens,⁴ Yutong Cai,⁵ Christian Schindler,^{2,3} Isabel Fortier,¹ Susan Hodgson,⁵ Amadou Gaye,⁶ Ronald Stolk,⁷ and Anna Hansell⁵

¹Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada

²Swiss Tropical and Public Health Institute, Basel, Switzerland

³University of Basel, Basel, Switzerland

⁴Institute for Risk Assessment Sciences, Utrecht University, Utrecht, Netherlands

⁵MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK

⁶National Human Genome Research Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA ⁷University Medical Center Groningen, Groningen, Netherlands

BACKGROUND: Research examining associations between air pollution exposure and respiratory symptoms in adults has generally been inconclusive. This may be related in part to sample size issues, which also preclude analysis in potentially vulnerable subgroups.

OBJECTIVES: We estimated associations between air pollution exposures and the prevalence of wheeze and shortness of breath using harmonized baseline data from two very large European cohorts, Lifelines (2006–2013) and UK Biobank (2006–2010). Our aim was also to determine whether the relationship between air pollution and respiratory symptom prevalence differed between individuals with different characteristics.

METHODS: Cross-sectional analyses explored associations between prevalence of self-reported wheeze and shortness of breath and annual mean particulate matter with aerodynamic diameter $<2.5 \mu$ m, $2.5-10 \mu$ m, and $<10 \mu$ m (PM_{2.5}, PM_{coarse}, and PM₁₀, respectively) and nitrogen dioxide (NO₂) concentrations at place of residence using logistic regression. Subgroup analyses and tests for interaction were performed for age, sex, smoking status, household income, obesity status, and asthma status.

RESULTS: All PM exposures were associated with respiratory symptoms based on single-pollutant models, with the largest associations seen for PM_{2.5} with prevalence of wheezing {odds ratio (OR) = 1.16 per 5 μ g/m³ [95% confidence interval (CI): 1.11, 1.21]} and shortness of breath [OR = 1.61 per 5 μ g/m³ (95% CI: 1.45, 1.78)]. The association between shortness of breath and a 5- μ g/m³ increment in PM_{2.5} was significantly higher for individuals from lower-[OR = 1.73 (95% CI: 1.52, 1.97)] versus higher-income households [OR = 1.31 (95% CI: 1.11, 1.55); *p*-interaction = 0.005), whereas the association between PM_{2.5} and wheeze was limited to lower-income participants [OR = 1.30 (95% CI: 1.22, 1.38) vs. OR = 1.02; (95% CI: 0.96, 1.08); *p*-interaction <0.001]. Exposure to NO₂ also showed positive associations with wheeze and shortness of breath.

CONCLUSION: Exposure to PM and NO₂ air pollution was associated with the prevalence of wheeze and shortness of breath in this large study, with stronger associations between $PM_{2.5}$ and both outcomes among lower- versus higher-income participants. https://doi.org/10.1289/EHP1353

Introduction

In 2010, ambient particulate matter (PM) air pollution was ranked as the ninth overall highest attributable burden risk factor and was estimated to cause 3.1 million premature deaths and 3.1% of disability adjusted life years (DALYs) worldwide (Lim et al. 2012). Chronic obstructive pulmonary disease (COPD), acute lower respiratory disease (ALRD), and lung cancer accounted for 28% of deaths attributable to ambient air pollution in 2012 (WHO 2016). Ambient air pollution is also thought to increase the risk of asthma exacerbation and asthma onset in children and adults (Guarnieri and Balmes 2014).

Respiratory symptoms such as wheezing and shortness of breath are indicators of airway inflammation associated with chronic respiratory diseases such as COPD, emphysema, and asthma, among other conditions (Abramson et al. 2002). Wheezing is caused by narrowed or compressed lower airways, which leads to turbulent airflow (Loudon and Murphy 1984). Shortness of breath is broadly defined as a subjective feeling of breathing discomfort. It can be characterized by a sense of respiratory effort/work, chest tightness, "air hunger"/unsatisfied inspiration, or a combination of these symptoms (Parshall et al. 2012). Wheezing usually relates to respiratory dysfunction, whereas breathlessness can be caused by cardiac as well as by respiratory dysfunction (Bozkurt and Mann 2003). Smoking and environmental tobacco smoke are important risk factors for COPD and for asthma development and symptoms (Janson et al. 2001; Leuenberger et al. 1994). Like cigarette smoke, ambient air pollution is a source of particulate matter exposure, but research on the relationship between air pollution and wheeze and shortness of breath prevalence in adults has largely been inconsistent (Brunekreef and Holgate 2002) despite evidence for air pollution impacts on respiratory mortality and asthma exacerbation (Fischer et al. 2015; Guarnieri and Balmes 2014).

Ambient air pollution was associated with incident asthma in a follow-up study of never smokers in the Swiss Study on Air Pollution and Lung Disease in Adults (SAPALDIA) cohort (41 cases) (Künzli et al. 2009), and authors of a combined longitudinal analysis of six European cohorts (including SAPALDIA) reported weak positive associations between air pollution and the incidence of adult asthma (1,257 cases) (Jacquemin et al. 2015). Data collected from >8,500 SAPALDIA participants in 1991 and 2002 suggested that living near a major street or highway was positively associated with attacks of breathlessness in the previous 12 months (Bayer-Oglesby et al. 2006). Residential ambient

Address correspondence to D. Doiron, Research Institute of the McGill University Health Centre, 2155 rue Guy, office 458, Montreal, Canada, H3H 2R9. Telephone: 1-514-934-1934 (ex. 71688). Email: ddoiron@ maelstrom-research.org

Supplemental Material is available online (https://doi.org/10.1289/EHP1353).

The authors declare they have no actual or potential competing financial interests.

Received 13 November 2016; Revised 10 August 2017; Accepted 14 August 2017; Published 29 September 2017.

Note to readers with disabilities: *EHP* strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in *EHP* articles may not conform to 508 standards due to the complexity of the information being presented. If you need assistance accessing journal content, please contact ehponline@niehs.nih.gov. Our staff will work with you to assess and meet your accessibility needs within 3 working days.

air pollutant concentrations were also associated with the prevalence of breathlessness, but not wheeze, in a cross-sectional study of 9,651 adults in the SAPALDIA cohort (Zemp et al. 1999). However, outdoor air pollution was associated with incident wheeze (1,023 cases) and incident asthma (254 cases) in a longitudinal analysis of a cohort of adult women in the United States (Young et al. 2014), and a study of 2,628 U.S. male veterans reported an association between residential proximity to a major roadway and persistent wheeze during the past year (Garshick et al. 2003). Lastly, a cross-sectional survey in Netherlands reported that 673 adults living along busy streets were more likely to report shortness of breath during walking, but not wheeze, than 812 adults living along streets in the same neighborhoods that had little traffic (Oosterlee et al. 1996). Many of these studies had limited numbers of participants (and cases), resulting in imprecise estimates of associations between air pollution exposures and respiratory health outcomes and in an inability to explore factors that might modify associations.

PM and nitrogen dioxide (NO₂) are commonly used as markers of ambient air pollutant exposures for epidemiologic studies. In the context of the BioSHaRE (Biobank Standardisation and Harmonisation for Research Excellence in the European Union) program, we harmonized and combined data from two of Europe's largest population health studies, the Lifelines Cohort Study and Biobank (Stolk et al. 2008) and UK Biobank (UK Biobank 2007), to explore associations of residential PM and NO₂ exposures with the prevalence of wheeze and shortness of breath in cohorts as a whole and in potentially vulnerable population subgroups. To our knowledge, this is the largest study of associations between respiratory symptoms and air pollution to date.

Methods

Study Populations

Both the Lifelines and UK Biobank cohorts sampled their participants from the general population using general practice registers. Baseline questionnaire and physical measures data were collected from 152,180 adult Lifelines participants (18-93 y of age) during 2006–2013 (Stolk et al. 2008) and from 502,655 UK Biobank participants (40-69 y of age) during 2006-2010 (UK Biobank 2007). The Lifelines cohort was designed to include three generations of study participants. An initial set of participants was identified from general practice patients residing in the three northern-most provinces of Netherlands (Friesland, Groningen, and Drenthe), which are largely rural regions (Klijs et al. 2015; Scholtens et al. 2015). The initial group of eligible participants comprised adults who were 25-50 y of age who did not have a severe psychiatric or physical illness or a limited life expectancy and who were able to complete the Dutch-language study questionnaire. Participants were asked to identify family members who might also want to participate in the study, and adult residents of the study provinces also could volunteer directly to participate in the study. Individuals were identified and invited to join the UK Biobank cohort via population-based registries such as those held by the National Health Service. Invitations were stratified according to key sociodemographic factors (e.g., age, sex, and postcode areas as a measure of social deprivation), with over-sampling of particular groups to enhance generalizability and to account for the impact of participation rates (UK Biobank 2007). UK Biobank study participants lived within approximately 25 miles of one of 22 assessment centers across Scotland, England, and Wales, in mostly urban areas (Allen et al. 2012). Full study sampling methods and participant selection criteria have been defined elsewhere (Allen et al. 2012; Scholtens et al. 2015; Stolk et al. 2008; UK Biobank 2007). Participants in both studies provided written informed consent at recruitment for broad use of their data by local and international investigators. We submitted research protocols and data access applications to the Lifelines and UK Biobank ethics and scientific review boards and obtained all necessary approvals.

Standardized Air Pollution Data

We used annual average concentrations of NO₂ and of particulate matter with aerodynamic diameter $<10 \ \mu m \ (PM_{10})$, fine particles with diameter $<2.5 \ \mu m$ (PM_{2.5}), and coarse particles with diameter between 2.5 μ m and 10 μ m (PM_{coarse}) at place of residence for the periods 2009-2010 (Lifelines) and 2010-2011 (UK Biobank). These air pollution estimates were generated in the context of the European Study of Cohorts for Air Pollution Effects (ESCAPE) using a standardized land-use regression (LUR) modeling approach. ESCAPE LUR models developed for Netherlands/ Belgium and for southeast England (i.e., London and Oxford) were employed for the Lifelines and UK Biobank study areas, respectively. Geographic information systems (GIS)-derived predictor variables were used to model spatial variation of measured annual air pollutant concentrations in each area, and model performance was evaluated using leave-one-out cross-validation (see Tables S1 and S2). Modeled PM_{2.5}, PM₁₀, and NO₂ performed relatively well in the Netherlands/Belgium area (cross-validation $R^2 = 61\%$, 60%, and 80%, respectively) and in the southeast England area (cross-validation $\bar{R}^2 = 82\%$, 90%, and 89%, respectively). PM_{coarse} cross-validation R^2 results were lowest in both areas (38% in the Netherlands/Belgium area; 57% in the southeast England area). Details of the ESCAPE LUR model development and validation methodology have been described elsewhere (Beelen et al. 2013; Eeftens et al. 2012).

For our study, home addresses of Lifelines and UK Biobank participants at the baseline assessment were geocoded and linked to LUR ESCAPE air pollution estimates. Because a significant proportion of UK Biobank participants resided in areas outside the initial southeast England ESCAPE study area, we tested the transferability of the LUR models using historical monitoring data from the United Kingdom's Automatic Urban and Rural Network (AURN) (Gulliver and de Hoogh 2015). The southeast England ESCAPE LUR model was applied to all UK AURN site locations, and associations between the LUR-modeled and AURN-measured NO₂ and PM₁₀ concentrations were analyzed by distance bands radiating from the edge of the ESCAPE study area.

Data Harmonization

To ensure data compatibility in our project, all respiratory symptoms and covariates used in statistical analyses went through a structured data harmonization process (Doiron et al. 2013; Fortier et al. 2016). As a first step, common-format respiratory outcome and confounding variables required for coanalyses were identified, and the possibility for each cohort to generate these variables was determined using information extracted from questionnaires, data dictionaries (i.e., codebooks), and standard operating procedures. Once "target" variables were defined and the harmonization potential was determined, processing algorithms written in the JavaScript programming language were implemented in Opal data harmonization software (Doiron et al. 2017) to map data collected from each cohort to a common (i.e., harmonized) format. Lastly, to validate the harmonized data sets, we conducted consistency and logic checks to verify counts and distributions of missing data, value ranges, and recoded variables.

Respiratory symptoms were collected through self-administered surveys at the baseline assessments for Lifelines and UK Biobank using different questionnaire assessment items (see Table S3). Both

studies collected data on prevalence of wheeze and shortness-ofbreath symptoms. Lifelines collected nonperiod-specified prevalence of wheeze ("Have you had wheezing or whistling in your chest at any time?"), wheezing without a cold ("Have you had this wheezing or whistling when you did not have a cold?"), and wheezing combined with shortness of breath ("Have you been at all breathless when the wheezing noise was present?"). UK Biobank collected information on wheezing in the last year ("In the last year, have you ever had wheeze or whistling in the chest?"). Lifelines participants reported shortness of breath at rest, whereas the UK Biobank questionnaire asked about shortness of breath while walking on level ground. Neither cohort included a recall time period for shortness of breath, and only $\sim 35\%$ of UK Biobank participants had data for this question because it was not added to the baseline survey until 2009. To account for heterogeneity of study-specific assessment items, the harmonized wheeze and shortness-of-breath symptom variables were respectively defined as follows: "presence of wheezing symptoms in the past year or more" and "shortness of breath at rest or when walking on level ground" (see Table S4).

We identified sociodemographic and behavioral risk factors to include as potential confounders and for exploring subgroups of vulnerability through literature review and based on data collected from each cohort (see Table S3). Common-format baseline assessment variables for age, sex, body mass index (BMI) (derived from measured height and weight), household income, highest level of education attained, current passive smoking exposure, and smoking status were defined and harmonized across cohorts (Table S4). For example, we performed the following procedures to derive a common-format variable for disposable household income. First, we derived a net annual household income variable for each cohort. For Lifelines, this variable was based on responses to a question about average monthly household income after taxes. For UK Biobank participants, we adjusted self-reported information on gross annual household income to reflect net income by subtracting estimates of participants' annual tax payments, which were obtained from the UK Government Web Archive (Directgov 2009). Next, we used data from the Organisation for Economic Cooperation and Development (OECD) (http://stats.oecd.org/) to derive a dichotomous income variable defined as "less than or equal to" or "greater than" the country-specific net mean household income for the United Kingdom (20,585 GBP) and Netherlands (25,600 EUR) in 2010.

Statistical Analysis

Harmonized data were analyzed using the DataSHIELD federated analysis method (Gaye et al. 2014; Wolfson et al. 2010). DataSHIELD involves setting up secure servers hosting harmonized data in geographically dispersed research centers and allowing a central analysis computer to conduct remote statistical analyses of individual-level data without the need to physically pool the data. DataSHIELD relies on three main components, all of which are open-source and freely available: Opal data management and harmonization software (Doiron et al. 2017), the R statistical programming environment (version 3.3.2; R Development Core Team), and DataSHIELD-specific R packages. For this project, harmonized data sets were hosted on separate servers at the University Medical Center Groningen in Netherlands (Lifelines data) and the Research Institute of the McGill University Health Centre in Canada (UK Biobank data). For an in-depth description of DataSHIELD implementation in the BioSHaRE project, see Gaye et al. (2014).

We used separate logistic regression models to estimate associations between annual average exposures to $PM_{2.5}$, PM_{coarse} , PM_{10} , and NO_2 at each participant's residence and self-reported wheezing (in the last year for UK Biobank, at any time for Lifelines; yes/no) and shortness of breath (when walking on level ground for UK Biobank, at rest for Lifelines, with no time period specified for either study; yes/no). For each respiratory symptom, we conducted pooled and study-specific logistic regression models in sequential stages, gradually adjusting for potential confounders to better examine their impact on effect estimates. To facilitate comparisons, these models were restricted to participants with data for all covariates in the fully adjusted model. A first minimally adjusted model included age as a continuous variable and sex (male/female) as confounders. In a second model, we further adjusted for BMI (kilograms per meter squared) [as normal (BMI < 25), overweight (BMI = 25 to < 30), or obese $(BMI \ge 30)$, where BMI was calculated from objectively assessed height and weight], highest level of education attained (less than or equal to secondary education/greater than postsecondary education), and annual net household income (less than or equal to/ greater than the country-specific mean for disposable household income in 2010). The fully adjusted model added smoking status (nonsmoker/past smoker/current smoker) and passive smoking (not exposed at home or work/exposed) to the second model. All pooled models also included a study indicator variable. Using the fully adjusted model, we conducted sensitivity analyses by restricting analyses to study participants living at the same (baseline) address for ≥ 5 years and ≥ 10 years. We also conducted two-pollutant models by adding NO2 as a confounder to the fully adjusted PM regression models and adding PM2.5 as a confounder to the NO2 model. We also explored the prevalence of wheeze and shortness of breath according to smoking status and passive smoking exposure to investigate the accuracy of symptom reporting, assuming that individuals exposed to tobacco smoke would have higher symptom prevalence.

Using the third fully adjusted model, we carried out subgroup analyses and tests for interaction to explore whether associations with residential air pollution exposure differed between individuals with different characteristics. Analyses stratified according to age (<65 vs. \geq 65 y), sex, smoking status (never smoked vs. current/former smokers), household income (≤country-specific mean disposable household income vs. >country-specific mean disposable household income), obesity status [obese (BMI \ge 30 kg/m²) vs. nonobese], and self-reported asthma status ("ever had asthma" vs. "never had asthma") were performed. We tested potential effect modification by including interaction terms in studyspecific and pooled analyses. Given potential confounding due to differences in the effects of subgroup variables on respiratory symptoms across studies, we added a second interaction term between the study indicator variable and the respective subgroup variable to the pooled model. Based on the existing literature, we hypothesized increased susceptibility to air pollution among the elderly, smokers, lower-income individuals, obese individuals, and individuals with asthma. Results were considered statistically significant at a level of p < 0.05 throughout.

Results

When compared with historical monitoring data, the southeast England ESCAPE NO₂ model predicted concentrations reasonably well ($R^2 = 0.67$) across the United Kingdom going back to 2006. For PM₁₀, the LUR model predicted concentrations moderately well up to 400 km away from the initial ESCAPE study area ($R^2 = 0.53$). All PM analyses were therefore restricted to UK Biobank residential addresses within 400 km of the southeast England area.

Figure 1 shows flow diagrams outlining study populations, exclusions, and missing data. By the time of the present study, the home addresses of 82,959 (54.5%) of the 152,180 participants



Figure 1. Lifelines and UK Biobank study population flow diagram. Note: NO_2 , nitrogen dioxide; PM, particulate matter. ¹By the time of this study, home addresses of 82,959 participants had not yet been geocoded by Lifelines data managers ²Residential addresses of 33,934 UK Biobank participants were excluded for all PM measures because they were farther than 400 km away from the original European Study of Cohorts for Air Pollution Effects (ESCAPE) monitoring area in southeast England. ³Only 35% of UK Biobank subjects had data for shortness of breath because it was added to the baseline survey late in the recruitment phase (i.e., as of 2009).

had not yet been geocoded by Lifelines data managers (geocoding was performed in the order of participant recruitment). For UK Biobank, 7,393 (1.5%) of the 502,655 residential addresses could not be geocoded. An additional 33,934 residential addresses were excluded from all PM measures because they were farther than 400 km away from the ESCAPE monitoring area in southeast England. Residential NO₂ and PM exposure estimates were therefore available for 495,262 and 461,328 UK Biobank participants, respectively. The household income variable was missing for 17% of Lifelines participants and for 15% of UK Biobank participants, and 16% of UK Biobank participants had no data for the passive smoking exposure variable. Finally, only 35% of UK Biobank participants had data for shortness of breath because this item was added to the baseline survey late in the recruitment phase (i.e., as of 2009).

Population characteristics and respiratory symptom prevalence for each cohort are presented in Table 1. Women comprised 57 and 53% of the Lifelines and UK Biobank participants, respectively. On average, UK Biobank participants were older, had higher BMI, and had lower educational attainment than Lifelines participants. The mean household income levels were comparable across study populations. There was a higher proportion of current smokers and of individuals exposed to secondhand smoke in Lifelines than in UK Biobank. The prevalence of self-reported respiratory symptoms was approximately the same across cohorts, with 1 in 5 participants reporting wheeze and 1 in 10 reporting shortness of breath. Pooled data showed the prevalence of wheeze was higher in former smokers (20.93%) and current smokers (27.08%) than in never smokers (16.43%), and it was higher in those exposed versus not exposed to passive smoke (23.84% vs. 17.22%) (see Table S5). Shortness of breath was also more common in former and current smokers (11.07%) and 11.52%, respectively) than in never smokers (8.85%) and in those exposed versus not exposed to passive smoke (13.45%) vs. 8.8%. These patterns were also evident for the individual cohorts (see Table S5).

Table 2 presents descriptive statistics for air pollutants. On average, Lifelines participants were exposed to higher PM and lower NO₂ concentrations than UK Biobank participants. For all air pollutants, the UK Biobank study area had a wider range. In both studies, annual mean concentrations of PM₁₀ were highly correlated with PM_{coarse} (Lifelines r=0.87; UK Biobank r=0.81) and PM_{2.5} (Lifelines r=0.78; UK Biobank r=0.53). Annual mean NO₂ concentrations were highly correlated with PM_{2.5} in UK Biobank (r=0.87) but not in Lifelines (r=0.42) and with PM_{coarse} in Lifelines (r=0.77) but not in UK Biobank (r=0.19) (Table 2).

The addition of confounders between pooled logistic regression models 1 through 3 gradually reduced the size of associations between air pollutants and respiratory symptoms (see Table S6) for both addition of socioeconomic status (SES) and BMI variables (model 1 to 2) and for smoking variables (model 2 to 3). The relative degree of attenuation was greater for wheeze than for shortness of breath, although PM_{2.5} and shortness of breath showed the largest absolute change in the odds ratio (OR) from the minimally adjusted OR of 2.10 (model 1) to 1.69 (model 2) to 1.61 (model 3). Fully adjusted pooled and cohort-specific results are shown in Table 3. In the pooled analyses, exposure to PM_{2.5} was positively associated with wheeze [OR = 1.16 per 5 μ g/m³ (95% CI: 1.11, 1.21)] and shortness of breath [OR = 1.61 per 5 μ g/m³ (95% CI: 1.45, 1.78)]. PM_{coarse} exposure showed a positive nonsignificant association with wheeze prevalence [OR =

Table 1. Population characteristics and respiratory symptom prevalence.

	Lifelines	UK Biobank	UK Biobank
Characteristic	n = 52,064	Wheeze and NO ₂ analyses; $n = 350,639$	Shortness of breath and NO ₂ analyses; $n = 121,550$
Male, % (<i>n</i>)	43.2 (22,487)	47.3 (165,717)	47.3 (57,486)
Female, $\%$ (<i>n</i>)	56.8 (29,577)	52.7 (184,922)	52.7 (64,064)
Age, mean \pm SD	42.6 ± 11.5	56.2 ± 8.1	56.5 ± 8.1
Age, % (<i>n</i>)			
<65 y	96.5 (50,233)	82.5 (289,278)	81.2 (98,689)
≥65 y	3.5 (1,831)	17.5 (61,361)	18.8 (22,861)
BMI, $\%$ (<i>n</i>)			
Normal ($<25 \text{ kg/m}^2$)	47.4 (24,650)	33.3 (116,585)	33.5 (40,767)
Overweight $(25-29.9 \text{ kg/m}^2)$	38.7 (20,146)	43 (150,657)	42.6 (51,735)
Obese $(\geq 30 \text{ kg/m}^2)$	14 (7,268)	23.8 (83,397)	23.9 (29,048)
Education level, $\%$ (<i>n</i>)			
Secondary education or lower, $\%$ (<i>n</i>)	24.9 (12,936)	35.3 (123,925)	34.3 (41,676)
Postsecondary education, $\%$ (<i>n</i>)	75.1 (39,128)	64.7 (226,714)	65.7 (79,874)
Household income, $\%$ (<i>n</i>)			
Mean or below mean country-specific net disposable income	48.4 (25,215)	45.2 (158,600)	45.2 (54,903)
Higher than mean country-specific net disposable income	51.6 (26,849)	54.8 (192,039)	54.8 (66,647)
Smoking status, $\%$ (<i>n</i>)			
Current smoker	23.7 (12,345)	3 (10,453)	3 (3,670)
Former smoker	30.4 (15,813)	38.1 (133,703)	38 (46,191)
Never smoker	45.9 (23,960)	58.9 (206,483)	59 (71,689)
Passive smoking exposure, $\%$ (<i>n</i>)			
Not exposed to secondhand smoke at home or at work	73.5 (38,264)	77.74 (272,604)	77.9 (94,708)
Exposed to secondhand smoke at home or at work	26.5 (13,800)	22.26 (78,035)	22.1 (26,842)
Wheeze, $\%$ (<i>n</i>)			
Has not had wheeze symptoms	79.7 (41,466)	81.6 (286,276)	_
Has had wheeze symptoms	20.4 (10,596)	18.4 (64,363)	_
Shortness of breath, $\%^a(n)$			
Has not had shortness of breath symptoms	90 (46,859)		90.2 (109,584)
Has had shortness of breath symptoms	10 (5,205)		9.8 (11,966)
Asthma, $\%^{b}(n)$			
Has had asthma	8.1 (4,203)	11.6 (40,680)	11.5 (13,967)
Has not had asthma	91.9 (47,686)	88.4 (309,729)	88.5 (107,495)

Note: For participants with complete data in fully adjusted model for age, sex, BMI, income, education, smoking status, passive smoking exposure. ---, UK Biobank wheeze preva-Note: For participants with complete data in tury aujusted model for age, sex, pint, medine, cureation, sinearing status, passive sinearing exposite a period provide the shown in second data column and shortness of breath prevalence shown in third data column; BMI, body mass index; SD, standard deviation. ^aOnly 35% of UK Biobank subjects had data for shortness of breath because it was added to the baseline survey late in the recruitment phase (i.e., as of 2009).

^bAn additional 175 participants had missing data for the asthma status variable in Lifelines. In the UK Biobank, 230 participants and 88 participants had missing data for asthma status for wheeze and NO₂ analyses and shortness of breath and NO₂ analyses, respectively.

1.05 per 5 μ g/m³ (95% CI: 1.00, 1.10)] and a statistically significant association with shortness-of-breath symptoms [OR = 1.28]per 5 μ g/m³ (95% CI: 1.15, 1.42)]. Residential exposure to NO₂ also showed significant associations with both wheeze and shortness of breath.

In two-pollutant models, the association between PM2.5 and wheeze was robust to adjustment for NO2, but the association between $PM_{2.5}$ and shortness of breath was not (Table 3). Associations of PM_{10} and PM_{coarse} were attenuated to the null for both outcomes when adjusted for NO2. The association between

Table 2. European Study of Cohorts for Air Pollution Effects (ESCAPE)-based annual average air pollution concentrations at place of residence for the	periods
2009–2010 (Lifelines) and 2010–2011 (UK Biobank) in micrograms per cubic meter and correlation matrix.	

			Percentiles			Correlation	coefficients (r)	
Pollutant	mean \pm SD	5th	50th	95th	PM _{2.5}	PM_{10}	PM _{coarse}	NO ₂
PM _{2.5}								
Pooled	10.72 ± 0.98	9.22	10.66	12.39	_	_	_	_
Lifelines	15.55 ± 0.36	15.27	15.45	16.25	1	0.78	0.37	0.42
UK Biobank	9.95 ± 1.04	8.26	9.90	11.78	1	0.53	0.21	0.87
PM ₁₀								
Pooled	17.29 ± 1.78	14.55	17.06	20.92		_	_	_
Lifelines	24.23 ± 0.68	23.73	23.95	25.49		1	0.87	0.74
UK Biobank	16.18 ± 1.90	13.08	16.00	20.19		1	0.81	0.50
PM _{coarse}								
Pooled	6.73 ± 0.85	6.00	6.43	9.12			_	_
Lifelines	8.68 ± 0.46	8.29	8.52	9.60			1	0.77
UK Biobank	6.41 ± 0.90	5.63	6.10	9.04			1	0.19
NO ₂								
Pooled	25.45 ± 7.13	14.40	24.35	36.93				_
Lifelines	16.48 ± 3.78	11.93	15.68	23.38				1
UK Biobank	26.28 ± 7.53	14.79	25.74	39.09				1

Note: For participants with complete data for wheeze, age, sex, BMI, income, education, smoking status, passive smoking exposure (Lifelines n = 52,062; UK Biobank n = 325,892). -, pooled correlation coefficients not performed; BMI, body mass index; NO2, nitrogen dioxide; PM2.5, particulate matter with aerodynamic diameter <2.5 µm; PM10, particulate matter with aerodynamic diameter $<10 \ \mu m$; PM_{coarse}, particulate matter with aerodynamic diameter 2.5–10 μm ; SD, standard deviation.

cohort and pooled) and for	r pooled two-pollutant mo	dels.						
	Lifelin	les ^a	UK Biob	ank ^a	Poole	qa	Pooled two-pollu	tant model ^{b,c}
Exposure and outcome	Cases/noncases (n/n)	OR (95% CI)	Cases/noncases (n/n)	OR (95% CI)	Cases/noncases (n/n)	OR (95% CI)	Cases/noncases (n/n)	OR (95% CI)
Wheeze								
$PM_{2.5}$ (per 5 µg/m ³)	10,596/41,466	$1.51 (1.12, 2.03)^{*}$	60,184/265,708	$1.15(1.10, 1.20)^{*}$	70,780/307,174	$1.16(1.11, 1.21)^{*}$	70,780/307,174	$1.22(1.12, 1.32)^{*}$
PM_{10} (per 5 µg/m ³)	10,596/41,466	$1.20 (1.02, 1.41)^{*}$	60,184/265,708	$1.02 (1.00, 1.05)^{*}$	70,780/307,174	$1.03 (1.01, 1.05)^{*}$	70,780/307,174	1.00(0.97, 1.03)
PM_{coarse} (per $5 \mu g/m^3$)	10,596/41,466	1.15(0.90, 1.46)	60,184/265,708	1.04(0.98, 1.09)	70,780/307,174	1.05(1.00, 1.10)	70,780/307,174	1.02 (0.97, 1.07)
NO ₂ (per $10 \mu g/m^3$)	10,596/41466	$1.11 \ (1.05, 1.18)^{*}$	64,363/286,276	$1.02 (1.01, 1.03)^{*}$	74,959/327,742	$1.03(1.02, 1.04)^{*}$	70,780/307,174	0.98 (0.96, 1.01)
Shortness of breath								
$PM_{2.5}$ (per 5 µg/m ³)	5,205/46,859	1.07 (0.72, 1.58)	11,958/109,538	$1.61(1.44, 1.79)^{*}$	17,163/156,397	$1.61 (1.45, 1.78)^{*}$	17,163/156,397	1.04(0.89, 1.23)
PM_{10} (per 5 µg/m ³)	5,205/46,859	$1.30 (1.06, 1.60)^{*}$	11,958/109,538	$1.17(1.11, 1.24)^*$	17,163/156,397	$1.20(1.14, 1.27)^{*}$	17,163/156,397	1.04(0.97, 1.10)
PM_{coarse} (per $5 \mu g/m^3$)	5,205/46,859	$1.73 (1.28, 2.35)^{*}$	11,958/109,538	$1.15(1.03, 1.29)^{*}$	17,163/156,397	$1.28(1.15, 1.42)^{*}$	17,163/156,397	1.08 (0.97, 1.21)
NO ₂ (per $10 \mu g/m^3$)	5,205/46,859	$1.20 \ (1.11, 1.29)^{*}$	11,966/109,584	$1.14 \ (1.11, 1.17)^{*}$	17,171/156,443	$1.16(1.13, 1.19)^{*}$	17,163/156,397	$1.15\ (1.10,\ 1.19)^{*}$
Note: CI, confidence interval;	NO2, nitrogen dioxide; OR, c	odds ratio; PM _{2.5} , particul	ate matter with aerodynamic	: diameter <2.5 μm; PM	0, particulate matter with aer	rodynamic diameter <10	µm; PM _{coarse} , particulate ma	tter with aerodynamic
diameter 2.5–10 µm; SD, stan	dard deviation. $*p < 0.05$.	-			100 J		-	
Adjusted for age (continuous). Sex. body mass index (norm	nal. overweight, or opese), household income (annual	net income $<$ or $>$ une c	OUNTRY-Specific mean for 201	0), education level (\leq se	scondary or postsecondary).	smoking status (never.

Table 3. Logistic regression model estimates of associations between annual average air pollution exposures at the baseline residence and respiratory symptoms for fully adjusted single-pollutant models (by

are adjusted for NO₂; two-pollutant models for NO₂ are adjusted for PM_{2.5} former, or current), passive smoking exposure (none or any), and cohort (Lifelines or UK Biobank). Pooled models also include an indicator term for the study (Lifelines or UK Biobank). oarse Two-pollutant models for PM2.5, PM10, and PM NO₂ and shortness of breath was not affected by adjustment for PM_{2.5}, but NO₂ was not associated with wheeze after adjustment (Table 3). Associations between pollutant exposure at residence and wheeze and shortness of breath were generally unchanged when restricting analyses to participants who lived at the same address for \geq 5 y and \geq 10 y (see Table S7).

Figures 2 and 3 outline pooled subgroup analyses for exposure to PM_{2.5} and PM_{coarse}, respectively. PM_{2.5} exposure was not associated with wheeze in higher-income individuals [OR = 1.02](95% CI: 0.96, 1.08) per 5 μ g/m³] but was associated with wheeze in lower-income participants [OR = 1.30 (95% CI: 1.22, 1.38); *p*-interaction <0.001]. Moreover, the association between shortness of breath and a $5-\mu g/m^3$ increment in PM_{2.5} was significantly higher among individuals from lower-income households [adjusted OR = 1.73 (95% CI: 1.52, 1.97)] than among higherincome individuals [adjusted OR = 1.31 (95% CI: 1.11, 1.55); p-interaction = 0.005]. Age, smoking status, and asthma status also modified associations between PM2.5 and wheeze symptoms, with slightly stronger associations for those ≥ 65 years of age (vs. <65; *p*-interaction = 0.004), past or current smokers (vs. never smokers; *p*-interaction < 0.001) and people without asthma (vs. those with asthma; *p*-interaction = 0.005). With regard to PM_{2.5}, the association between PM_{coarse} and shortness of breath was stronger for lower-income participants than for higher-income participants [OR = 1.41 (95% CI: 1.24, 1.61) vs. 1.09 (95% CI: (0.91, 1.30); *p*-interaction = (0.009) although there was no clear difference in the association between PMcoarse and wheeze according to income. Lastly, PMcoarse was associated with shortness of breath among nonobese participants [OR = 1.41 (95% CI: 1.23, 1.63)] but not among obese participants [OR = 1.02 (95%)]CI: 0.87, 1.20); *p*-interaction = 0.002].

Both PM_{10} and NO_2 were associated with wheeze in lowerincome individuals but not in higher-income participants (see Figures S1 and S2). Associations between NO_2 (but not PM_{10}) and shortness of breath were also significantly stronger for lowerincome individuals than for higher-income participants (see Figures S1 and S2). Lastly, interaction for obesity status was observed for PM_{10} and NO_2 associations with shortness of breath, with nonobese participants showing significantly stronger associations.

Discussion

In this pooled study, we found statistically significant associations between mean annual PM and NO₂ exposure and selfreported wheeze and shortness-of-breath symptoms. The strongest estimated associations were between fine particulate matter and self-reported shortness-of-breath symptoms, although there was little evidence of an association after adjustment for NO₂. The use of large biobanks resulted in a large sample size that provided good statistical power to explore potentially vulnerable population subgroups. Our estimates suggested stronger associations of PM2.5 with both wheeze and shortness-of-breath symptoms, and of PM_{coarse} with shortness of breath, among participants with lower incomes compared with those with higher incomes. Associations between PM2.5 and wheeze were significantly higher among older versus younger participants, past or current smokers versus never smokers, and people without versus with asthma. In addition, PM_{coarse} was associated with shortness of breath among nonobese participants, but not among obese participants.

A previous longitudinal analysis of data from six European cohorts that also used ESCAPE exposure estimates reported positive but nonsignificant associations of NO_2 , nitrogen oxides (NO_x), and PM exposure metrics with asthma incidence (Jacquemin et al. 2015), and another analysis based on data from four of these six cohorts reported nonsignificant positive

	Number of	Wheeze	Odds ratio	Interaction
	participants	 Shortness of breath 	(95 % 01)	F-value
Sex				
Males	176854 79947 201100		1.16 [1.09 - 1.23] 1.57 [1.34 - 1.85] 1.15 [1.09 - 1.22]	.451 <i>.867</i>
Females	93613		1.62 [1.42 - 1.85]	
Age				
Under 65	318950 148873		1.14 [1.09 - 1.19] 1.68 [1.50 - 1.89]	.004 . <i>802</i>
65 and older	59004 24687		1.29 [1.17 - 1.43] 1.61 [1.28 - 2.01]	
Income				
Low	173657 80101 204297	_ _	1.30 [1.22 - 1.38] 1.73 [1.52 - 1.97] 1.02 [0.96 - 1.08]	<.001 .005
High	93459		1.31 [1.11 - 1.55]	
Obesity status				
Non-obese	293097 137253	_ _	1.13 [1.07 - 1.19] 1.68 [1.46 - 1.93]	.068 . <i>100</i>
Obese	36307		1.45 [1.25 - 1.70]	
Smoking Status				
Never smoked	215185 95568	_ _	1.08 [1.02 - 1.15] 1.71 [1.48 - 1.97]	<.001 .233
Past or current smoker	162769 77992		1.25 [1.18 - 1.33] 1.49 [1.29 - 1.73]	
Asthma status				
Non-asthmatic	335245 155134		1.19 [1.13 - 1.25] 1.58 [1.41 - 1.78]	.005 .857
Asthmatic	42316 18163		1.11 [1.00 - 1.23] 1.67 [1.34 - 2.08]	
		1 1.5 2 OR (95% CI)		

Figure 2. Adjusted odds ratios [and 95% confidence intervals (CIs)] for respiratory symptoms in association with a 5- μ g/m³ increase in ambient particulate matter with aerodynamic diameter <2.5 μ m (PM_{2.5}) at participant residences among population subgroups based on pooled data from the Lifelines and UK Biobank cohorts. Logistic regression model adjusted for age (continuous), sex, body mass index (BMI) (normal, overweight, or obese), household income (annual net income \leq or > the country-specific mean for 2010), education level (\leq secondary or postsecondary), smoking status (never, former, or current), passive smoking exposure (none/any), and cohort (Lifelines/UK Biobank). Interaction *p*-values are Wald *p*-values for product interaction terms between air pollutants and stratification variables. Non-italic *p*-values (top), wheeze symptoms; Italic *p*-values (bottom), shortness-of-breath symptoms.

associations of NO₂, NO_x, and PM₁₀ with COPD prevalence and incidence (Schikowski et al. 2014). More recently, significant positive associations were reported for PM₁₀ and NO₂ exposures (estimated using ESCAPE models) with lifetime asthma prevalence (a self-reported history of ever having had asthma) and current asthma (a self-reported history of asthma plus current or recent use of asthma medications) in a combined analysis of data from UK Biobank, Lifelines, and the Norwegian Nord-Trøndelag Health Study (HUNT3) cohorts (Cai et al. 2017). Associations between air pollutants and prevalent wheeze based on our analysis of UK Biobank and Lifelines data were similar to those reported by Cai et al. (2017) for lifetime asthma prevalence. Specifically, for a $5-\mu g/m^3$ increase in $PM_{2.5}$, we estimated OR = 1.16 (95% CI: 1.11, 1.21) compared with OR = 1.11 (95% CI: 1.07, 1.16); for a $5 - \mu g/m^3$ increase in PM_{10} , we estimated OR = 1.03 (95% CI: 1.01, 1.05) compared with OR = 1.04 (95% CI: 1.01, 1.06); for a $5 - \mu g/m^3$ increase in PM_{coarse} , we estimated OR = 1.05 (95% CI: 1.00, 1.10) compared with OR = 1.04 (95% CI: 0.99, 1.09); and for a $10-\mu g/m^3$ increase in NO₂, we estimated OR = 1.03 (95% CI: 1.02, 1.04) compared with OR = 1.02 (95% CI: 1.01, 1.04) from Cai et al. (2017).

Associations between air pollutants and shortness of breath were stronger than corresponding associations with wheeze in our study population, which might be consistent with cardiovascular effects (Ebi-Kryston 1988) rather than (or in addition to) respiratory effects. A previous study of residential ambient air pollutant concentrations in Swiss adults reported associations with the prevalence of breathlessness, but not wheeze (Zemp et al. 1999), and adults living along busy streets in Netherlands were more likely to report shortness of breath during walking, but not wheeze, than adults living along low-traffic streets in the same neighborhoods (Oosterlee et al. 1996). However, these findings may also represent reporting misclassification: although individuals diagnosed with asthma are likely to recognize the symptom of wheeze, the rest of the population might not and

	Number of participants	Wheeze	Odds ratio (95% Cl)	Interaction P-value
Sex		• Shortness of breath		
Males Females	176854 79947 201100		1.01 [0.94 - 1.08] 1.31 [1.11 - 1.54] 1.08 [1.01 - 1.16]	.220 .803
A.z.a	93613	•	1.27 [1.10 - 1.45]	
Age				
Under 65	318950 148873		1.04 [0.99 - 1.10] 1.35 [1.20 - 1.51]	.637 <i>.258</i>
65 and older	59004 24687		1.07 [0.95 - 1.20] 1.15 [0.91 - 1.46]	
Income				
Low	173657 80101 204297	•	1.07 [1.00 - 1.15] 1.41 [1.24 - 1.61] 1.03 [0.96 - 1.10]	.443 .009
High	93459		1.09 [0.91 - 1.30]	
Obesity status				
Non-obese	293097 137253 84857	- -	1.02 [0.96 - 1.08] 1.41 [1.23 - 1.63] 1.09 [1.00 - 1.19]	.184 <i>.002</i>
Obese	36307	•	1.02 [0.87 - 1.20]	
Smoking Status				
Never smoked	215185 95568		1.04 [0.97 - 1.11] 1.28 [1.11 - 1.48]	. <mark>526</mark> <i>.820</i>
Past or current smoker	162769 77992	- -	1.06 [0.99 - 1.14] 1.28 [1.10 - 1.49]	
Asthma status				
Non-asthmatic	335245 155134	- -	1.05 [0.98 - 1.11] 1.25 [1.11 - 1.41]	.940 .240
Asthmatic	42316 18163	•	1.07 [0.95 - 1.20] 1.48 [1.18 - 1.85]	
		1 1.5 OR (95% CI)	2	

Figure 3. Adjusted odds ratios [and 95% confidence intervals (CIs)] for respiratory symptoms in association with a 5- μ g/m³ increase in ambient particulate matter with aerodynamic diameter 2.5–10 μ m (PM_{coarse} at participant residences among population subgroups based on pooled data from the Lifelines and UK Biobank cohorts. Logistic regression model adjusted for age (continuous), sex, body mass index (BMI) (normal, overweight, or obese), household income (annual net income \leq or > the country-specific mean for 2010), education level (\leq secondary or postsecondary), smoking status (never, former, or current), passive smoking exposure (none/any), and cohort (Lifelines/UK Biobank). Interaction *p*-values are Wald *p*-values for product interaction terms between air pollutants and stratification variables. Non-italic *p*-values (top), wheeze symptoms; Italic *p*-values (bottom), shortness-of-breath symptoms.

therefore might label the symptom as shortness of breath. Wheeze is not always well recognized in the general population. In the seminal International Study of Asthma and Allergies in Childhood (ISAAC), many countries used a video to demonstrate wheezing symptoms without using the word wheezing and asked if the child had these symptoms, as well as using a written questionnaire using the word "wheezing." Results comparing prevalence tertiles determined using the video versus those determined using the written questionnaire were discordant in a third of centers (Beasley 1998).

Our study provides evidence in line with previous reports that lower household income may be associated with greater impact of particulate matter pollution on respiratory health (Wheeler and Ben-Shlomo 2005), which is of concern because lower-SES individuals are potentially more likely to have higher exposures. As shown in a recent neighborhood-level study conducted in the same countries as these cohorts (i.e., Netherlands and the United Kingdom), the highest particulate matter and NO₂ concentrations were consistently found in the most deprived areas in both countries (Fecht et al. 2015). Lower-SES individuals might be more susceptible to health effects of air pollution exposures because of coexposures to other environmental stressors (e.g., housing conditions, occupational exposures) or because of comorbid conditions related to reduced access to health care or to lifestyle, diet, and other factors (Lipfert 2004).

A review of factors associated with increased susceptibility to the health effects of air pollution suggested that older individuals and people with asthma are at increased risk (Sacks et al. 2011), consistent with our findings. Although some previous studies have reported evidence suggesting that obese people are more susceptible to health effects of air pollution than nonobese people (Sacks et al. 2011), we estimated stronger associations between PM_{coarse} , PM_{10} , and NO_2 and shortness of breath among nonobese individuals than among obese individuals in our study population. A subjective increase in shortness of breath among obese individuals might largely be explained by decreased respiratory muscle function and higher levels of systemic inflammation (Carpio et al. 2016), and any additional impact of air pollution on breathlessness could be negligible in this subgroup.

Multipollutant modeling has been proposed as a solution to the problem of double counting or overestimating the effects of any one pollutant (Héroux et al. 2015). In our study, the association between $PM_{2.5}$ and wheeze was robust to adjustment for NO_2 , and the association between NO_2 and shortness of breath was robust to adjustment for $PM_{2.5}$, whereas other associations were attenuated to the null after adjustment for a second pollutant. However, the two-pollutant model results should be interpreted with caution because of the different sample sizes, the high correlation between pollutants, and the different pollutant correlation structures across the cohorts included in this study.

Fine particulates (i.e., PM_{2.5}) have been reported to have stronger associations with respiratory or cardiovascular mortality relative to coarse (i.e., PM_{2.5-10}) particulates (Brunekreef and Forsberg 2005; Faustini et al. 2014). This difference might be explained by a wider diffusion of fine particulates in the respiratory tract and by a stronger systemic inflammatory response. However, PM_{coarse} has been shown to have as strong or stronger short-term effects on COPD, asthma, and respiratory hospital admissions (Brunekreef and Forsberg 2005). For wheeze symptoms, we found consistently stronger associations with $PM_{2.5}$ than with PM_{coarse} exposure in pooled and study-specific analyses. The association between PM_{coarse} and shortness of breath was stronger than the association between PM_{2.5} and shortness of breath in the Lifelines cohort, where participants were asked if they had ever had an attack of shortness of breath during the day when they were at rest. In contrast, the association between PM_{2.5} and shortness of breath was stronger than the association between PM_{coarse} and shortness of breath in the UK Biobank cohort, where participants were asked if they had ever had shortness of breath while walking. These divergent results might reflect differences between the study populations in the composition and sources of coarse particles, the data collection instruments used by each cohort, the way in which participants interpreted the questions about shortness of breath, or other factors (Gjersing et al. 2010; Guillemin et al. 1993). Further, whereas the UK Biobank questionnaire collected period-specific wheeze prevalence (i.e., in the last year), the lack of a specified period in the Lifelines assessment item might have led to recall bias. To help overcome such challenges in the future, new studies should make use of internationally validated questionnaires whenever possible. Implementing standardized questionnaires on asthma and COPD respiratory symptoms and risk factors in epidemiological studies would greatly facilitate comparing and pooling data (Pistelli and Maio 2014).

A few limitations with regard to exposure assessment should be noted. First, because no information on study participants' work addresses or time-activity patterns was available in either cohort, air pollution exposure was only estimated at the home address. A study that compared exposures estimated with and without accounting for daily mobility in the metropolitan Vancouver, British Columbia area and in southern California found that estimates that did not account for mobility were biased toward the null, with greater bias when the spatial variability of pollution was higher (Setton et al. 2011). Second, applying the ESCAPE southeast England LUR models to the larger UK Biobank study area could have led to exposure measurement error. However, LUR models provided good predictions of historical NO₂ concentrations across the United Kingdom ($R^2 =$ 0.67) and good predictions of PM_{10} concentrations within a 400-km radius of the initial ESCAPE study area ($R^2 = 0.53$) (Gulliver and de Hoogh 2015).

Pooled analyses would have been more strongly influenced by data from the UK Biobank cohort than from the Lifelines cohort because of the larger number of UK Biobank observations included in the analyses. Further, although only 45% of total Lifelines participants had been attributed air pollution exposure estimates, we do not expect selection bias to have been a major problem because participant residences were geocoded in chronological order (i.e., in the order of recruitment) rather than according to any given participant characteristic. Residual confounding, exposure and outcome misclassification, and other potential sources of bias are also possible. Finally, given the cross-sectional nature of our analyses, we cannot confirm the temporal relationship between air pollution exposures and the respiratory symptoms in our study population.

Conclusion

In conclusion, the findings from our cross-sectional analysis of data from adult cohorts in the United Kingdom and Netherlands add to existing evidence of the adverse effects of ambient air pollution on respiratory health in adults. In addition, differences in associations among population subgroups may reflect differences in susceptibility according to age, SES, and other factors.

Acknowledgments

The authors wish to acknowledge the services of the staff at UK Biobank and the Lifelines Cohort Study, the contributing research centers delivering data on these two cohorts, and all the study participants. We also acknowledge the ESCAPE project for their work in developing the air pollution exposure assessments used in our study. Lastly, we would like to thank Y. Marcon (Research Institute of the McGill University Health Centre, Montreal, Canada), P. Burton and D. Avraam (School of Social and Community Medicine, Bristol, UK), and C. Pang (University Medical Center Groningen, Groningen, Netherlands) for their support in implementing DataSHIELD federated analyses. Opensource software and the methodology used to harmonize and analyze data across cohorts were developed by Maelstrom Research (www.maelstrom-research.org).

The research leading to these results received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 261433 [Biobank Standardisation and Harmonisation for Research Excellence in the European Union (BioSHaRE-EU)]. Y.C. acknowledges support from the Early-Career Research Fellowship awarded by the UK Medical Research Council – Public Health England Centre for Environment and Health (Grant number MR/M501669/1).

References

- Abramson M, Matheson M, Wharton C, Sim M. 2002. Prevalence of respiratory symptoms related to chronic obstructive pulmonary disease and asthma among middle aged and older adults. Respirology 7(4):325–331, PMID: 12421240, https://doi.org/10.1046/j.1440-1843.2002.00408.x.
- Allen N, Sudlow C, Downey P, Peakman T, Danesh J, Elliott P, et al. 2012. UK Biobank: current status and what it means for epidemiology. Health Policy Technol 1(3):123–126, https://doi.org/10.1016/j.hlpt.2012.07.003.
- Bayer-Oglesby L, Schindler C, Hazenkamp-von Arx ME, Braun-Fahrländer C, Keidel D, Rapp R, et al. 2006. Living near main streets and respiratory symptoms in adults: The Swiss Cohort Study on Air Pollution and Lung Diseases in Adults. Am J Epidemiol 164(12):1190–1198, PMID: 17032694, https://doi.org/10.1093/aje/kwj338.
- Beasley R. 1998. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 351(9111):1225–1232, PMID: 9643741, https://doi.org/10.1016/S0140-6736(97)07302-9.
- Beelen R, Hoek G, Vienneau D, Eeftens M, Dimakopoulou K, Pedeli X, et al. 2013. Development of NO₂ and NO_x land use regression models for estimating air pollution exposure in 36 study areas in Europe – the ESCAPE project. Atmos Environ 72:10–23, https://doi.org/10.1016/j.atmosenv.2013.02.037.
- Bozkurt B, Mann DL. 2003. Shortness of breath. Circulation 108(2):e11–e13, PMID: 12860894, https://doi.org/10.1161/01.CIR.0000075956.36340.78.

- Brunekreef B, Holgate ST. 2002. Air pollution and health. Lancet 360(9341):1233– 1242, PMID: 12401268, https://doi.org/10.1016/S0140-6736(02)11274-8.
- Brunekreef B, Forsberg B. 2005. Epidemiological evidence of effects of coarse airborne particles on health. Eur Respir J 26(2):309–318, PMID: 16055881, https://doi.org/10. 1183/09031936.05.00001805.
- Cai Y, Zijlema WL, Doiron D, Blangiardo M, Burton PR, Fortier I, et al. 2017. Ambient air pollution, traffic noise and adult asthma prevalence: a BioSHaRE approach. Eur Respir J 49(1):1502127, PMID: 27824608, https://doi.org/10.1183/ 13993003.02127-2015.
- Carpio C, Villasante C, Galera R, Romero D, de Cos A, Hernanz A, et al. 2016. Systemic inflammation and higher perception of dyspnea mimicking asthma in obese subjects. J Allergy Clin Immunol 137(3):718–726.e4, PMID: 26768410, https://doi.org/10.1016/j.jaci.2015.11.010.
- Directgov. 2009. Income tax and national insurance rates for 2010–11. http:// webarchive.nationalarchives.gov.uk/20100104175853/http://direct.gov.uk/en/NI1/ Newsroom/PreBudgetReport2009/DG_183037 [accessed 19 July 2017].
- Doiron D, Burton P, Marcon Y, Gaye A, Wolffenbuttel BH, Perola M, et al. 2013. Data harmonization and federated analysis of population-based studies: the BioSHaRe project. Emerg Themes Epidemiol 10(1):12, PMID: 24257327, https://doi.org/10.1186/ 1742-7622-10-12.
- Doiron D, Marcon Y, Fortier I, Burton P, Ferretti V. 2017. Opal and mica: opensource software solutions for epidemiological data management, harmonization and dissemination. Int J Epidemiol, https://doi.org/10.1093/ije/dyx180.
- Ebi-Kryston KL. 1988. Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study. J Clin Epidemiol 41(3):251–260, PMID: 3339378, https://doi.org/10.1016/0895-4356(88)90129-1.
- Eeftens M, Beelen R, de Hoogh K, Bellander T, Cesaroni G, Cirach M, et al. 2012. Development of land use regression models for PM_{2.5}, PM_{2.5} absorbance, PM₁₀ and PM_{coarse} in 20 European study areas; Results of the ESCAPE project. Environ Sci Technol 46(20):11195–11205, PMID: 22963366, https://doi.org/10.1021/ es301948k.
- Faustini A, Héroux M-E, Forastiere F. 2014. Outdoor air pollution. In: *Respiratory Epidemiology: ERS Monograph, Vol. 65.* Annesi-Maesano I, Lundbäck B, Viegi G, eds. Sheffield, UK:European Respiratory Society, 179–197.
- Fecht D, Fischer P, Fortunato L, Hoek G, de Hoogh K, Marra M, et al. 2015. Associations between air pollution and socioeconomic characteristics, ethnicity and age profile of neighbourhoods in England and the Netherlands. Environ Pollut 198:201–210, PMID: 25622242, https://doi.org/10.1016/j.envpol.2014.12.014.
- Fischer PH, Marra M, Ameling CB, Hoek G, Beelen R, de Hoogh K, et al. 2015. Air pollution and mortality in seven million adults: the Dutch Environmental Longitudinal Study (DUELS). Environ Health Perspect 123(7):697–704, PMID: 25760672, https://doi.org/10.1289/ehp.1408254.
- Fortier I, Raina P, Van den Heuvel ER, Griffith LE, Craig C, Saliba M, et al. 2016. Maelstrom Research guidelines for rigorous retrospective data harmonization. Int J Epidemiol 46(1):103–105, PMID: 27272186, https://doi.org/10.1093/ije/dyw075.
- Garshick E, Laden F, Hart JE, Caron A. 2003. Residence near a major road and respiratory symptoms in U.S. Veterans. Epidemiology 14(6):728–736, PMID: 14569190, https://doi.org/10.1097/01.ede.0000082045.50073.66.
- Gaye A, Marcon Y, Isaeva J, LaFlamme P, Turner A, Jones EM, et al. 2014. DataSHIELD: Taking the analysis to the data, not the data to the analysis. Int J Epidemiol 43(6):1929–1944, PMID: 25261970, https://doi.org/10.1093/ije/dyu188.
- Gjersing L, Caplehorn JR, Clausen T. 2010. Cross-cultural adaptation of research instruments: Language, setting, time and statistical considerations. BMC Med Res Methodol 10(1):13, PMID: 20144247, https://doi.org/10.1186/1471-2288-10-13.
- Guarnieri M, Balmes JR. 2014. Outdoor air pollution and asthma. Lancet 383(9928): 1581–1592, PMID: 24792855, https://doi.org/10.1016/S0140-6736(14)60617-6.
- Guillemin F, Bombardier C, Beaton D. 1993. Cross-cultural adaptation of healthrelated quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 46(12):1417–1432, PMID: 8263569, https://doi.org/10.1016/0895-4356(93)90142-N.
- Gulliver J, de Hoogh K. 2015. Environmental exposure assessment: Modelling air pollution concentrations. In: Oxford Textbook of Global Health. Detels R, Gulliford M, Karim Q, Tan C, eds. Oxford, UK:Oxford University Press.
- Héroux M-E, Anderson HR, Atkinson R, Brunekreef B, Cohen A, Forastiere F, et al. 2015. Quantifying the health impacts of ambient air pollutants: recommendations of a WH0/Europe project. Int J Public Health 60(5):619–627, PMID: 26024815, https://doi.org/10.1007/s00038-015-0690-y.
- Jacquemin B, Siroux V, Sanchez M, Carsin A-E, Schikowski T, Adam M, et al. 2015. Ambient air pollution and adult asthma incidence in six European cohorts (ESCAPE). Environ Health Perspect 123(6):613–621, PMID: 25712593, https://doi.org/ 10.1289/ehp.1408206.
- Janson C, Chinn S, Jarvis D, Zock J-P, Torén K, Burney P. 2001. Effect of passive smoking on respiratory symptoms, bronchial responsiveness, lung function, and

total serum IgE in The European Community Respiratory Health Survey: a crosssectional study. Lancet 358(9299):2103–2109, PMID: 11784622, https://doi.org/10. 1016/S0140-6736(01)07214-2.

- Klijs B, Scholtens S, Mandemakers JJ, Snieder H, Stolk RP, Smidt N. 2015. Representativeness of the LifeLines cohort study. PLOS One 10(9):e0137203, PMID: 26333164, https://doi.org/10.1371/journal.pone.0137203.
- Künzli N, Bridevaux P-O, Liu S, Garcia-Esteban R, Schindler C, Gerbase M, et al. 2009. Traffic-related air pollution correlates with adult-onset asthma among never-smokers. Thorax 64(8):664–670, PMID: 19359271, https://doi.org/10.1136/ thx.2008.110031.
- Leuenberger P, Schwartz J, Ackermann-Liebrich U, Blaser K, Bolognini G, Bongard JP, et al. 1994. Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA study). Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA team. Am J Respir Crit Care Med 150(5 Pt 1):1222–1228, PMID: 7952544, https://doi.org/10.1164/ajrccm.150.5.7952544.
- Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. 2012. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 380(9859):2224– 2260, PMID: 23245609, https://doi.org/10.1016/S0140-6736(12)61766-8.
- Lipfert FW. 2004. Air pollution and poverty: Does the sword cut both ways?. J Epidemiol Community Health 58(1):2–3, PMID: 14684716, https://doi.org/10.1136/ jech.58.1.2.
- Loudon R, Murphy RL Jr. 1984. Lung sounds. Am Rev Respir Dis 130(4):663–673, PMID: 6385790, https://doi.org/10.1164/arrd.1984.130.4.663.
- Oosterlee A, Drijver M, Lebret E, Brunekreef B. 1996. Chronic respiratory symptoms in children and adults living along streets with high traffic density. Occup Environ Med 53(4):241–247, PMID: 8664961, https://doi.org/10.1136/oem.53.4.241.
- Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. 2012. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 185(4):435–452, PMID: 22336677, https://doi.org/10.1164/rccm.201111-2042ST.
- Pistelli F, Maio S. 2014. Questionnaires and lung function. In: Respiratory Epidemiology: ERS Monograph, Vol. 65. Annesi-Maesano I, Lundbäck B, Viegi G, eds. Sheffield, UK:European Respiratory Society, 257–272.
- Sacks JD, Stanek LW, Luben TJ, Johns DO, Buckley BJ, Brown JS, et al. 2011. Particulate matter-induced health effects: Who is susceptible?. Environ Health Perspect 119(4):446–454, PMID: 20961824, https://doi.org/10.1289/ehp.1002255.
- Schikowski T, Adam M, Marcon A, Cai Y, Vierkötter A, Carsin AE, et al. 2014. Association of ambient air pollution with the prevalence and incidence of COPD. Eur Respir J 44(3):614–626, PMID: 24488569, https://doi.org/10.1183/ 09031936.00132213.
- Scholtens S, Smidt N, Swertz MA, Bakker SJL, Dotinga A, Vonk JM, et al. 2015. Cohort profile: LifeLines, a three-generation cohort study and biobank. Int J Epidemiol 44(4):1172–1180, PMID: 25502107, https://doi.org/10.1093/ije/dyu229.
- Setton E, Marshall JD, Brauer M, Lundquist KR, Hystad P, Keller P, et al. 2011. The impact of daily mobility on exposure to traffic-related air pollution and health effect estimates. J Expo Sci Environ Epidemiol 21(1):42–48, PMID: 20588325, https://doi.org/10.1038/jes.2010.14.
- Stolk R, Rosmalen JM, Postma D, de Boer R, Navis G, Slaets JJ, et al. 2008. Universal risk factors for multifactorial diseases. LifeLines: a three-generation populationbased study. Eur J Epidemiol 23(1):67–74, PMID: 18075776, https://doi.org/10.1007/ s10654-007-9204-4.
- UK Biobank. 2007. Protocol for a large-scale prospective epidemiological resource. http://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol. pdf [accessed 19 July 2017].
- Wheeler BW, Ben-Shlomo Y. 2005. Environmental equity, air quality, socioeconomic status, and respiratory health: a linkage analysis of routine data from the Health Survey for England. J Epidemiol Community Health 59(11):948–954, PMID: 16234422, https://doi.org/10.1136/jech.2005.036418.
- Wolfson M, Wallace SE, Masca N, Rowe G, Sheehan NA, Ferretti V, et al. 2010. DataSHIELD: resolving a conflict in contemporary bioscience—performing a pooled analysis of individual-level data without sharing the data. Int J Epidemiol 39(5):1372–1382, PMID: 20630989, https://doi.org/10.1093/ije/dyq111.
- WHO (World Health Organization). 2016. Ambient air pollution: a global assessment of exposure and burden of disease. http://who.int/phe/publications/air-pollutionglobal-assessment/en/ [accesed 19 July 2017].
- Young MT, Sandler DP, DeRoo LA, Vedal S, Kaufman JD, London SJ. 2014. Ambient air pollution exposure and incident adult asthma in a nationwide cohort of U.S. women. Am J Respir Crit Care Med 190(8):914–921, PMID: 25172226, https://doi.org/10.1164/rccm.201403-05250C.
- Zemp E, Elsasser S, Schindler C, KÜNzli N, Perruchoud AP, Domenighetti G, et al. 1999. Long-term ambient air pollution and respiratory symptoms in adults (SAPALDIA study). The SAPALDIA Team. Am J Respir Crit Care Med 159(4 Pt 1):1257– 1266, PMID: 10194174, https://doi.org/10.1164/ajrccm.1594.9807052.